Patrick H. van Berkel

858 total citations
35 papers, 496 citations indexed

About

Patrick H. van Berkel is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Patrick H. van Berkel has authored 35 papers receiving a total of 496 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 12 papers in Molecular Biology and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Patrick H. van Berkel's work include CAR-T cell therapy research (15 papers), HER2/EGFR in Cancer Research (11 papers) and Synthesis and pharmacology of benzodiazepine derivatives (9 papers). Patrick H. van Berkel is often cited by papers focused on CAR-T cell therapy research (15 papers), HER2/EGFR in Cancer Research (11 papers) and Synthesis and pharmacology of benzodiazepine derivatives (9 papers). Patrick H. van Berkel collaborates with scholars based in United Kingdom, Switzerland and United States. Patrick H. van Berkel's co-authors include Francesca Zammarchi, John A. Hartley, Simon Chivers, Philip W. Howard, David G. Williams, Simon Corbett, Arnaud Tiberghien, Carin E.G. Havenith, Peter Tyrer and Lauren Adams and has published in prestigious journals such as Blood, Cancer Research and Scientific Reports.

In The Last Decade

Patrick H. van Berkel

31 papers receiving 479 citations

Peers

Countries citing papers authored by Patrick H. van Berkel

Since Specialization

Citations

This map shows the geographic impact of Patrick H. van Berkel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick H. van Berkel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick H. van Berkel more than expected).

Fields of papers citing papers by Patrick H. van Berkel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick H. van Berkel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick H. van Berkel. The network helps show where Patrick H. van Berkel may publish in the future.

Co-authorship network of co-authors of Patrick H. van Berkel

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick H. van Berkel. A scholar is included among the top collaborators of Patrick H. van Berkel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick H. van Berkel. Patrick H. van Berkel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Lineage dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and -independent immunotherapeutic targets	Neuro-Oncology	Nathan M. Kendsersky, Nathaniel W. Mabe et al.	1
2	Targeting CD25 + lymphoma cells with the antibody–drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents	British Journal of Haematology	Filippo Spriano, Chiara Tarantelli et al.	2
3	Integrin-αvβ6 targeted peptide-toxin therapy in a novel αvβ6-expressing immunocompetent model of pancreatic cancer	Pancreatology	Nicholas F. Brown, Elizabeth Murray et al.	5
4	ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies	Molecular Cancer Therapeutics	Francesca Zammarchi, Karin Havenith et al.	6
5	Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant	Molecular Therapy	Jenny Yeung, Aiyin Liao et al.	6
6	Abstract 3122: Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6	Cancer Research	Elizabeth Horsley, Karin Havenith et al.	2
7	Abstract 2638: Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancers	Cancer Research	Francesca Zammarchi, Karin Havenith et al.	2
8	The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer–Containing Antibody–Drug Conjugates	Molecular Cancer Therapeutics	Simon Corbett, Shiran Huang et al.	14
9	Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus	Theranostics	Kate M. Moore, Ami V. Desai et al.	37
10	Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, with Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models	Blood	Shiran Huang, John A. Hartley et al.	6
11	Abstract 234: Pre-clinical characterization of 3A4-PL1601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) directed against KAAG1-expressing malignancies	Cancer Research	Francesca Zammarchi, Karin Havenith et al.	3
12	Abstract 4750: The role of drug transporters in the acquired resistance to PBD dimer-containing antibody drug conjugates	Cancer Research	Simon Corbett, Francesca Zammarchi et al.	1
13	APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo	Molecular Cancer Therapeutics	Alexander H. Staudacher, Yanrui Li et al.	15
14	Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine	Scientific Reports	John A. Hartley, Michael Flynn et al.	85
15	Abstract 51: Characterization of the mechanism of action, pharmacodynamics and preclinical safety of ADCT-402, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD19-expressing hematological malignancies	Cancer Research	Francesca Zammarchi, Simon Corbett et al.	1
16	Abstract 52: Mechanistic and benchmarking studies of ADCT-502, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors	Cancer Research	Francesca Zammarchi, Narinder Janghra et al.	4
17	ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies	Molecular Cancer Therapeutics	Michael Flynn, Francesca Zammarchi et al.	85
18	ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody–drug conjugate (ADC) targeting low HER2-expressing solid cancers	European Journal of Cancer	Francesca Zammarchi, Simon Chivers et al.	14
19	Mechanistic and Pharmacodynamic Studies of Adct-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies	Blood	Michael Flynn, Patrick H. van Berkel et al.	6
20	Pre-Clinical Development of Adct-402, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate (ADC) Targeting CD19-Expressing B-Cell Malignancies	Blood	Francesca Zammarchi, David G. Williams et al.	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact